Angle Share Discussion Threads

[gspanner] 13/5/2024 14:01

Looks like it… Big old bet that.

[boris cobaka] 13/5/2024 13:49

487k rollover?

The needle on the seismograph just ticked up a notch...

[countbasie1] 13/5/2024 13:36

Don't be caught underwears.

[kryptonsnake] 13/5/2024 13:32

they dropped the share price to help fill that 250k order

muppets continue to sell


sent from my iPhone

[kryptonsnake] 13/5/2024 13:30

boris

adw is more of a sell at the lows and continue to moan kind of guy


sent from my iPhone

[atmysignal] 13/5/2024 13:20

Blue today?Highly likely

[boris cobaka] 13/5/2024 12:58

That 250k delayed buy is Adw heh heh!

[boris cobaka] 13/5/2024 12:55

Morning Anglers!

Quiet as a cemetery or perhaps better to say dormant volcano.
Check for seismic activity....

[robizm] 13/5/2024 12:27

Blackhorse the funniest clown on advfn

[blackhorse23] 13/5/2024 10:14

Money moved to APH ( alliance Pharma )

[atmysignal] 13/5/2024 08:49

Lighten up. Don't take anonymous posters too seriously.

[adw198] 13/5/2024 08:22

Morning krypton / atmysignal

Let’s not worry about what time or day I post, what the weather is like when I post or whether you think I’m allowed to post. Let’s stick to the company.

I’ll stick with my view that revenue impacts the cash runway and krypton can have his view it’s irrelevant. And atmy signal can post “50p likely” half a dozen zen times a day. That way we all get to make a contribution. :)

[kryptonsnake] 13/5/2024 08:16

atmysignal

Yes Adw198 is a loon. One for the filter bin now

Attacks anyone with a bullish view even though he sold and has posted nothing but negativity ever since

Clearly needs help


sent from my iPhone

[liberatingsteptoe] 12/5/2024 23:19

today's DTel Questor: I can think of one Co they might be interested in...... Absolutely no information but it does make one think...... Just hope that things here progress for a while yet and that LTH get their just rewards.


Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.

The move – Abcam had made Aim its home since 2005 and was one of its biggest companies – was seen at the time as a blow to the Government’s efforts to champion the UK’s most innovative companies.

It was also an indication that the entire London listings market was in decline with many companies since being bought out by predators and seeking higher valuations overseas.

Abcam now has a new owner. Since late last year, the company has been part of Danaher Corporation, the New York-listed life sciences and diagnostics giant.

Danaher paid $5.7bn (£4.6bn) in cash for Abcam, which makes and sells products, including proteins and reagents, used in medical research. It has added the business to its already extensive array of medical products and services, which range from cell production and new drugs discovery to the instruments used in clinical testing.

In its former guise, Abcam had a devoted following among individual UK shareholders. Danaher has a fanbase of its own too: the world’s best fund managers.

Nine of them hold the stock, and each one is among the top 3pc of the 10,000 equity fund managers tracked by financial publisher Citywire. This smart-money backing has led to Danaher being AAA rated by Citywire Elite Companies, which rates companies based on their popularity with the world’s best-performing fund managers.

Danaher share price
Line chart with 1274 data points.
$ per share
View as data table, Danaher share price
The chart has 1 X axis displaying Time. Data ranges from 2019-04-22 00:00:00 to 2024-05-10 00:00:00.
The chart has 1 Y axis displaying $. Data ranges from 107.5989 to 294.6626.
$
2020
2021
2022
2023
2024
50
100
150
200
250
300
SOURCE: BLOOMBERG
Danaher share price
$ per share

End of interactive chart.
While Abcam is not transformational for Danaher – it represents just 2.5pc of overall revenue – top fund manager Neal Kaufman, who holds Danaher shares in the Baron Health Care Fund, says the deal underlines a key attribute: “This acquisition is reflective of Danaher’s thoughtful approach to acquisitions, through which the company has been able to add best-in-class assets in attractive end markets like bioprocessing and proteomics [the study of sets of proteins].”

Management, which has acquired hundreds of businesses since Danaher was created in 1984, is aiming to grow Abcam’s revenues by the high-single-digit percentages over the long term. This is in line with the wider group’s core growth target. It’s an impressive aim for a company of its scale which last year reported revenues just shy of $24bn.

Danaher’s management team is also happy to reshape the group’s portfolio of businesses with disposals.

Last year, for example, it spun off its environmental services arm Veralto to create a separately listed business now worth $24bn. It did the same with its $3.5bn dental operation, Envista, in 2019. In both cases, Danaher’s shareholders benefited, and it would be no surprise to see the company do something similar again.


There is plenty enticing Kaufman and the other leading fund managers backing the company beyond its savvy deals. Among these attractions is Danaher’s wide spread of products, high degree of recurring revenues and those punchy core growth targets already mentioned.

Across the company’s three business lines – of biotechnology, life sciences and diagnostics – around 80pc of revenue is recurring. This provides a striking degree of certainty in a sector where earnings can be volatile.

Danaher’s expertise in areas such as biologics, or medicines made using living cells or organisms, puts it at the cutting edge of new treatments for diseases such as cancer and autoimmune deficiencies. Growth should also benefit from rising demand for rapid diagnostics.

It’s not all plain sailing. Many smaller biotechs have been caught up in a funding crunch for the past two years and the group has lost orders as a result. The good news is that Danaher said earlier this month it had noticed an improvement, though this has yet to translate into an increase in orders.

Revenues also fell last year, and will again this year, as the effects of a Covid-related sales boost fade and customers finish running down excess stock.

Danaher is confident the lull will be short-lived and is sticking with its central growth targets. The wider market also appears optimistic based on the punchy rating attached to the shares of 32 times forecast earnings. That’s a price several of the world’s best professional investors think is worth paying. This column agrees.

Questor says: buy

Ticker: NYSE:DHR

Share price: $253.38

Read the latest Questor column on telegraph.co.uk every Sunday, Tuesday, Wednesday, Thursday and Friday from 5am.

Read Questor’s rules of investment before you follow our tips.

[atmysignal] 12/5/2024 23:08

This adw198 character is for real a loon.Relentless dialogue all weekend.All week, for that matter.Comes across angry and frustrated.Bit like Samantha Bones.

[adw198] 12/5/2024 21:55

Brilliant work spa - making several posts about how great things were whilst selling your own.

And then claiming some kind of moral high ground because you won’t comment if not invested.

Scummy and stupid.

[bones698] 12/5/2024 21:08

Spa fiar enough unlike some who can't seem to get over it..
Where this goes will be driven by news and results from here. I expect some more news on the bioview collaboration soon hence staying put and momentum is growing for now. Chart looks good so I don't think we have seen the peak yet. I base my decisions on actual news never off what gets said on a bb.
I did well. On the spike in jan. Happy to. See how it plays out for now.

Are you buying some sce for a punt?

[bagpuss67] 12/5/2024 20:49

Spa. Not a bad call or price.

[spa362] 12/5/2024 20:07

PS I am certainly not going to be trashing Angle just because I have sold out at this stage.

[spa362] 12/5/2024 20:05

Well hopefully I have been honest - I sold out at 23p with about £8k profit. I do think that this share could well achieve 50p overtime - and that would be quite justifiable as it grows. But I have my own risk/reward ratio which I apply. Perhaps people sometimes forget that the only reason to invest is to make money - not to bicker on bulletin boards or to be a ramper or de-ramper. Will be upfront if I re-invest.

[boris cobaka] 12/5/2024 19:19

Lol. Thanks for sharing.

[spa362] 12/5/2024 18:43

I must confess that I am now out of this stock with a healthy profit but still feel positive about future opportunities and may well get engaged again at some point. Good luck to all holders.

[adw198] 11/5/2024 23:04

Evening krpton, you said 30s then changed it to 25-30p. Doesn’t really matter though, the main thing is your well underwater here. And you were again wrong this week. You 100% didn’t sell any at 25p because nobody did.